%0 Journal Article
%T Post-natalizumab disease reactivation in multiple sclerosis:
systematic review and meta-analysis
%A Augusto A. Miravalle
%A Luca Prosperini
%A Pietro Iaffaldano
%A Revere P. Kinkel
%A Simone Fantaccini
%J Archive of "Therapeutic Advances in Neurological Disorders".
%D 2019
%R 10.1177/1756286419837809
%X Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly due to concerns about the risk of progressive multifocal leukoencephalopathy. However, NTZ interruption may result in recrudescence of disease activity
%K discontinuation
%K meta-analysis
%K natalizumab
%K relapsing¨Cremitting multiple sclerosis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444403/